Antitumor activity and toxicological properties of doxorubicin conjugated to α,β-poly[(2-hydroxyethyl)-L-aspartamide] administered intraperitoneally in mice

Anti-Cancer Drugs

Volumn 21, Issue 4, 2010, Pages 362-371

  Cheng, Xiaoyun ^a   Xue, Weihua ^a   Diao, Huajia ^a   Xia, Suhua ^a   Zuo, Longsheng ^a   He, Aijun ^a   Gao, Fengbo ^a   Huang, Zhen ^a   Chen, Jiangning ^a   Zhang, Junfeng ^a  

^a NANJING UNIVERSITY   (China)

Author keywords

, poly (2 hydroxyethyl) L aspartamide; Antitumor activity; Doxorubicin; Intraperitoneal chemotherapy; Polymer drug; Toxicity

Indexed keywords

ALPHA,BETA POLY[(2 HYDROXYETHYL) LEVO ASPARTAMIDE]; DOXORUBICIN; POLYMER; UNCLASSIFIED DRUG;

ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD CHEMISTRY; BODY WEIGHT; CANCER CELL CULTURE; CANCER INHIBITION; CELL STRAIN HEPG2; CONTROLLED STUDY; DRUG CONJUGATION; DRUG RELEASE; ELECTROCARDIOGRAPHY; FEMALE; HEART MUSCLE BIOPSY; HELA CELL; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; IN VIVO STUDY; LD 50; MOUSE; NONHUMAN; PRIORITY JOURNAL; SARCOMA 180; SURVIVAL TIME;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CELL LINE, TUMOR; CYTOTOXINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; FEMALE; HUMANS; INJECTIONS, INTRAPERITONEAL; MICE; MICE, INBRED ICR; PEPTIDES; SARCOMA 180;

EID: 77949422408     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e3283355227     Document Type: Article

References (38)

1. Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. Obstet Gynecol Surv 2006; 61:240-242.
2. Yan TD, Chu F, Links M, Kam PC, Glenn D, Morris DL. Cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma: non-mucinous tumour associated with an improved survival. Eur J Surg Oncol 2006; 32:1119-1124.
3. Sugarbaker PH, Mora JT, Carmignani P, Stuart OA, Yoo D. Update on chemotherapeutic agents utilized for perioperative intraperitoneal chemotherapy. Oncologist 2005; 10:112-122.
4. Jain D. Cardiotoxicity of doxorubicin and other anthracycline derivatives. J Nucl Cardiol 2000; 7:53-62.
5. DeAtley SM, Aksenov MY, Aksenova MV, Jordan B, Carney JM, Butterfield DA. Adriamycin-induced changes of creatine kinase activity in vivo and in cardiomyocyte culture. Toxicology 1999; 134:51-62.
6. Rose PG, Blessing JA, Lele S, Abulafia O. Evaluation of pegylated liposomal doxorubicin (Doxil) as second-line chemotherapy of squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol 2006; 102:210-213.
7. Zhang J, Chen XG, Li YY, Liu CS. Self-assembled nanoparticles based on hydrophobically modified chitosan as carriers for doxorubicin. Nanomedicine: N B M 2007; 3:258-265.
8. Schmid B, Chung DE, Warnecke A, Fichtner I, Kratz F. Albumin-binding prodrugs of camptothecin and doxorubicin with an Ala-Leu-Ala-Leu-linker that are cleaved by cathepsin B: synthesis and antitumor efficacy. Bioconjugate Chem 2007; 18:702-716.
9. Cao N, Feng SS. Doxorubicin conjugated to d-a-tocopheryl polyethylene glycol 1000 succinate (TPGS): conjugation chemistry, characterization, in vitro and in vivo evaluation. Biomaterials 2008; 29:3856-3865.
10. Kimura M, Konno T, Miyamoto Y, Kojima Y, Maeda H. Intracavitary administration: pharmacokinetic advantages of macromolecular anticancer agents against peritoneal and pleural carcinomatoses. Anticancer Res 1998; 18:2547-2550.
11. Colombo PE, Boustta M, Poujol S, Pinguet F, Rouanet P, Bressolle F, et al. Biodistribution of doxorubicin-alkylated poly(l-lysine citramide imide) conjugates in an experimental model of peritoneal carcinomatosis after intraperitoneal administration. Eur J Pharm Sci 2007; 31:43-52.
12. Pan H, Kopeèek J. Fundamental biomedical technologies. In: Torchilin VP, editor. Fundamental biomedical technologies, multifunctional pharmaceutical nanocarriers. Berlin: Springer Press; 2008. pp. 81-142.
13. Neri P, Antoni G, Benvenuti F, Cocola F, Gazzei G. Synthesis of a, b-poly [(2-hydroethyl)-D, L-aspartamide]-a new plasma expander. J Med Chem 1973; 16:893-897.
14. Giammona G, Cavallaro G, Pitarresi G. Studies of macromolecular prodrugs of zidovudine. Adv Drug Deliv Rev 1999; 39:153-164.
15. Giammona G, Cavallaro G, Fontana G, Pitarresi G, Carlisi B. Coupling of the antiviral agent zidovudine to polyaspartamide and in vitro drug release studies. J Controlled Release 1998; 54:321-331.
16. Cavallaro G, Licciardi M, Caliceti P, Salmaso S, Giammona G. Synthesis, physico-chemical and biological characterization of a paclitaxel macromolecular prodrug. Eur J Pharm Biopharm 2004; 58:151-159.
17. Cavallaro G, Maniscalco L, Campisi M, Schillaci D, Giammona G. Synthesis, characterization and in vitro cytotoxicity studies of a macromolecular conjugate of paclitaxel bearing oxytocin as targeting moiety. Eur J Pharm Biopharm 2007; 66:182-192.
18. Cavallaro G, Maniscalco L, Caliceti P, Salmaso S, Semenzato A, Giammona G. Glycosylated macromolecular conjugates of antiviral drugs with a polyaspartamide. J Drug Target 2004; 12:593-605.
19. Hreczuk-Hirst D, German L, Duncan R. Dextrins as carriers for drug targeting: reproducible as a means to introduce pendant groups. J Bioact Compat Pol 2001; 16:353-365.
20. Frauer D, Frigerio E, Pianezzola E, Strolin Benedetti M, Cassidy J, Vasey P. A sensitive procedure for the quantitation of free and N-(2-hydroxypropyl) methacylamide polymer-bound doxorubicin (PK1) and some of its metabolites, 13-dihydrodoxorubicin, 13-dihydrodoxorubicinone and doxorubicinone, in human plasma and urine by reversed-phase HPLC with fluorimetric detection. J Pharmaceut Biomed Anal 1995; 13:625-633.
21. Yang SR, Lee HJ, Kim JD. Histidine-conjugated poly (amino acid) derivatives for the novel endosomolytic delivery carrier of doxorubicin. J Controlled Release 2006; 114:60-68.
22. Li YC, Fung KP, Kwok TT, Lee CY, Suen YK, Kong SK. Mitochondrial targeting drug lonidamine triggered apoptosis in doxorubicin-resistant HepG2 cells. Life Sci 2002; 71:2729-2740.
23. Xu SY, Li L, Zhou JP, Lu SY, Yang J, Yin XJ, et al. Preparation and characterization of N-succinyl-N0-octyl chitosan micelles as doxorubicin carriers for effective anti-tumor activity. Colloids Surf B: Biointerfaces 2007; 55:222-228.
24. Jiang BH, Zhang L, Li M,Wua WY, Yang M,Wang JC, et al. Salvianolic acids prevent acute doxorubicin cardiotoxicity in mice through suppression of oxidative stress. Food Chem Toxicol 2008; 46:1510-1515.
25. Sacco G, Bigioni M, Evangelista S, Goso C, Manzini S, Maggi CA. Cardioprotective effects of zofenopril, a new angiotensin-converting enzyme inhibitor, on doxorubicin-induced cardiotoxicity in the rat. Eur J Pharmacol 2001; 414:71-78.
26. Nyblom H, Berggren U, Balldin J, Olsson R. High AST/ALT ratio may indicate advanced alcoholic liver, disease rather than heavy drinking. Alcohol Alcohol 2004; 39:336-339.
27. Mohamed HE, EL-Swefy SE, Hagar HH. The protective effect of glutathione administration on adriamycin-induced acute cardiac toxicity in rats. Pharm Res 2000; 42:115-121.
28. Vasey PA, Kaye SB, Morrison R. Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl) methacrylamide copolymer doxorubicin]: First member of a new class of chemotherapeutic agents-DRUG-polymer conjugates. Clin Cancer Res 1999; 5:83-94.
29. Julyan PJ, Seymour LW, Ferry DR, Daryani S, Boivin CM, Doran J, et al. Preliminary clinical study of the distribution of HPMA copolymers bearing doxorubicin and galactosamine. J Controlled Release 1999; 57:281-290.
30. Song Y, Onishi H, Machida Y, Nagai T. Drug release and antitumor characteristics of N-succinyl-chitosan-mitomycin C as an implant. J Controlled Release 1996; 42:93-100.
31. Hovorka O, S t'astný M, Etrych T, Subr V, Strohalmb J, Ulbrich K, et al. Differences in the intracellular fate of free and polymer-bound doxorubicin. J Controlled Release 2002; 80:101-117.
32. Etrych T, Chytil P, Mrkvan T, S ? ?́rová M, Ø?́hová B, Ulbrich K. Conjugates of doxorubicin with graft HPMA copolymers for passive tumor targeting. J Controlled Release 2008; 132:184-192.
33. Seymour LW, Miyamoto Y, Maeda H, Brereton M, Strohalm J, Ulbrich K, et al. Influence of molecular weight on passive tumour accumulation of a soluble macromolecular drug carrier. Eur J Cancer 1995; 31:766-770.
34. Iyer AK, Khaled G, Fang J, Maeda H. Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov Today 2006; 11:812-818.
35. Gautier S, Boustta M, Vert M. Alkylated poly (l-lysine citramide) as models to investigate the ability of amphiphilic macromolecular drug carriers to physically entrap lipophilic compounds in aqueous media. J Controlled Release 1999; 60:235-247.
36. Bab?́è ek K, È echová I, Simon RR, Harwood M, Cox DJ. Toxicological assessment of a particulate yeast (1,3/1,6)-b-D-glucan in rats. Food Chem Toxicol 2007; 45:1719-1730.
37. Di Stefano G, Derenzini M, Kratz F, Lanza M, Fiume L. Liver-targeted doxorubicin: effects on rat regenerating hepatocytes. Liver Int 2004; 24:246-252.
38. Pereverzeva E, Treschalin I, Bodyagin D, Maksimenko O, Langer K, Dreis S, et al. Influence of the formulation on the tolerance profile of nanoparticlebound doxorubicin in healthy rats: Focus on cardio- and testicular toxicity. Int J Pharm 2007; 337:346-356.